EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures H1 2025: Earnings positive but below prior year – net sales stable – significant increase in order intake – forecast confirmed

Ad-hoc notification in accordance with Sec. 17 of the MAR

Drägerwerk AG & Co. KGaA: Preliminary figures H1 2025: Earnings positive but below prior year – net sales stable – significant increase in order intake – forecast confirmed

Lübeck, July 11, 2025 – Based on preliminary calculations, Dräger generated positive earnings before interest and taxes (EBIT) of around EUR 20 million in the first half of 2025. However, EBIT did not reach the significantly higher prior-year figure (6 months 2024: EUR 55.8 million). This was due in particular to the positive one-off effects in the prior year: in the second quarter of 2024, Dräger had sold a non-strategic business area in the Netherlands and a property in the U.S. for a total of around EUR 20 million. These earnings contributions are now missing. The EBIT margin amounted to around 1.3 percent in the first half of 2025 (6 months 2024: 3.7 percent).

Net sales remained almost stable with an increase of 0.4 percent (net of currency effects; nominal: -0.7 percent) to around EUR 1,510 million (6 months 2024: EUR 1,520.5 million). Following a decline in the prior year, the medical division recorded growth in net sales of 1.8 percent (net of currency effects; nominal: 0.6 percent) to around EUR 851 million (6 months 2024: EUR 846.3 million). The safety division recorded a decline of 1.4 percent (net of currency effects; nominal: -2.2 percent) to around EUR 659 million (6 months 2024: EUR 674.2 million). The Group's gross margin remained stable at around 44.8 percent.

Demand for Dräger products and services developed very well in the first half of the year. Order intake grew significantly by around 10.1 percent (net of currency effects; nominal: 8.3 percent) to around EUR 1,738 million. This not only exceeded the high prior-year level (6 months 2024: EUR 1,604.3 million), but also reached the highest level for a first half-year since the record half-year 2020. Both divisions contributed to this positive development: after a decline in the prior year, order intake in the medical division rose significantly by 14.8 percent (net of currency effects; nominal: 12.3 percent) to around EUR 1,011 million (6 months 2024: EUR 900.1 million); this is due in particular to the good performance in the second quarter. In the safety division, order intake increased by 4.2 percent (net of currency effects; nominal: 3.3 percent) to around EUR 727 million (6 months 2024: EUR 704.3 million).

Business performance in the second quarter of 2025
Order intake rose significantly in the second quarter by 14.3 percent (net of currency effects; nominal: 10.5 percent) to around EUR 877 million (Q2 2024: EUR 793.5 million). In the medical division, it increased strongly by 25.5 percent (net of currency effects; nominal: 20.3 percent) to around EUR 537 million (Q2 2024: EUR 446.4 million) after a decline in the prior year. This was due in particular to a major multi-year order from Mexico in the mid double-digit million euro range. In the safety division, order intake was almost on par (net of currency effects: -0.1 percent; nominal: -2.0 percent) with the prior year at EUR 340 million (Q2 2024: EUR 347.1 million).

Net sales grew by 1.8 percent (net of currency effects; nominal: -0.6 percent) to around EUR 780 million (Q2 2024: EUR 784.7 million). Following a decline in the prior year, the medical division recorded an increase of 5.0 percent (net of currency effects; nominal: 2.1 percent) to around EUR 438 million (Q2 2024: EUR 428.8 million). The safety division recorded a decline of 2.0 percent (net of currency effects; nominal: -3.9 percent) to around EUR 342 million (Q2 2024: EUR 355.8 million). The Group's gross margin was around 43.8 percent (Q2 2024: 44.3 percent). EBIT amounted to around EUR 20 million (Q2 2024: EUR 40.7 million). The EBIT margin amounted to around 2.6 percent (Q2 2024: 5.2 percent).

Due to the very good order development, Dräger continues to expect an increase in net sales of 1.0 to 5.0 percent (net of currency effects) and an EBIT margin of 3.5 to 6.5 percent for the current fiscal year.

The full results for the first six months of the fiscal year will be published on July 29, 2025.

Drägerwerk AG & Co. KGaA
Moislinger Allee 53–55
23558 Lübeck, Germany
www.draeger.com

Investor Relations:
Thomas Fischler
Tel. +49 451 882-2685
thomas.fischler@draeger.com

Corporate Communications:
Melanie Kamann
Tel. +49 451 882-3998
melanie.kamann@draeger.com

Disclaimer
This ad hoc report contains statements on the future development of Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to date. They were compiled to the best of the company's knowledge. Dräger does not provide any warranty nor assume any responsibility for the future developments and results described above. These are dependent on a number of factors. They entail various risks and contingencies outside of the company's influence and are based on assumptions which could prove to be incorrect. Dräger does not assume any responsibility for updating the forward-looking statements contained in this report. This does not infringe any legal stipulations on the adjustment of forecasts. Please go to Investor Relations / Definitions of financial indicators at www.draeger.com for information on alternative performance measures used.